TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Clearance rate of Actinic Keratoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety of Ecallantide
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Ecallantide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: individual learning parameters
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Analgesic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days with headache per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine Specific Quality of Life Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient understanding of discharge instructions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: development of oral mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Tenofovir Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Estradiol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Testosterone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Anxiety questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: energy target fulfilling rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: protein target fulfilling rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glutamate Concentration During a Visual Stimulus at Normoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Glutamate Concentration During a Visual Stimulus at Hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression Free Rate (PFR) at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Neurocognitive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cancer-related physical fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Detection of hookworm eggs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pulmonary volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects with an increase in Spontaneous Complete Bowel Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection of ventricular arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Short-term antithrombotic management patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of quetiapine titration
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With HIV-1 RNA Less Than 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and Negative Syndromes Scale (PANSS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Human ghrelin half life
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Biochemical assessment of hyperandrogenism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Child Sheehan Disability Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Health-Related Quality of Life and Functioning: Physical Health Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Health-Related Quality of Life and Functioning: Mental Health Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Morphine Milligram Equivalent (MME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-hours blood glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Persistence of antibodies to Engerix-B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunological Response to Challenge Dose (Anti-HBs Antibody Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change in perceived pain scores on the visual analog scale at day 1 post-partum
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in perceived pain scores on the visual analog scale at day 4 post-partum
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of Surgical Stereotactic Navigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of immune changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Eye Tracking: Fixation Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye Tracking: Dwell Duration Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Reward Ball-tossing Task
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Non-Social Reward Ball-tossing Game
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Facial Emotion Identification Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in ARI/ILI/GI infections
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Absenteeism
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in Presenteeism
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of all related serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Health Related Quality of Life: Short Form-36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health resource use: hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of New-onset Category II or III Fetal Heart Rate Tracings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in peak expiratory flow (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ejaculatory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: orgasm perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overdose Risk Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum markers of bone resorption and formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone mass density of the lumbar spine and proximal femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Reported Quality of Communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Comprehensive advance care planning documentation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: DN-4 Interview Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of patients' management
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: combined MRI synovitis, osteitis and tendinitis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiac death, myocardial infarction or coronary revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Inhibition of maximum fall in FEV1 after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 3 year event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Acute radiation-induced dermatitis of grade 2 or higher
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants in Clinical Remission (Based on Modified Disease Activity Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cue Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of insulin residual effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proteins and cellular markers related to coagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: [18F]-ML-10 uptake in the target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cases of synovial sarcoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: plasma protein C activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain Beliefs Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Variation of Hb level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants with treatment-emergent Grade≥3 AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with treatment-emergent Grade≥2 imAEs
Endpoint domain: Adverse events/effects
Primary endpoint: change in mGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Stability of cooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of leg ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Thoracic Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load drop from baseline through Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who developed confirmed Stage II or greater hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in platelet count from baseline through Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: embolus capture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of contractions per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Beta cell graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CNAQ-score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Consumer Assessment of Healthcare Providers and Systems (CAHPS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: dislocation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Platelet Function as Assessed by Thromboelastography (TEG) Platelet Mapping (PM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nasal Blood Flow to the Sinonasal Mucosa as Assessed by the Rhinolux System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Number of Vaccine Doses Created Using Participant Tumor Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity to House Dust Mite (HDM) allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Primary Menopause-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnosis of significant fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Reduction in substance abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sexual risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Reduction in victimization
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Exercise Capacity (6-minute Walk Distance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline of serum β-HCG to an undetectable level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Neurocognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Social cognition
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Area under the glucose infusion rate curve (GIR-AUC0-end)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prognosis of patients with angina equivalent symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in number of pills taken at 4 weeks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline in number of pills taken at 12 weeks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rates of sterilization of blood cultures after 72 hours of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: SCOLISCORE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal Residual Disease (MRD) Negative Complete Response (CR) in the Bone Marrow at 2 Months Post FCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Minimal Residual Disease (MRD) Negative Complete Response (CR) in the Bone Marrow at 2 Years Post Discontinuation of Ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Balance Function Assessment-Sensory Organization Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance Function Assessment- Adaptation Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualised Rate of Moderate to Severe COPD Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Numbers of manual adjustments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical efficacy assessed by CT scan and bone marrow aspirate and biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVD outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attainment of Minimal Clinically Important Difference in Erectile Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Th17 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: flare-up confirmed by coloscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of HIV patients with a measurable proviral reservoir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum troponin T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with QOL decline exceeding 2 x MID
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Burke Lateropulsion Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Flow Mediated Dilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Concentration (Cmax) of Serum Total Iron After Intraperitoneal Administration of Triferic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve (AUC) Last of Serum Total Iron After Intraperitoneal Administration of Triferic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve (AUC) 0 - 12 of Serum Total Iron After Intraperitoneal Administration of Triferic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft Tissue Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax, maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Who Received Rescue Medication Midazolam
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change of best corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of motor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing rate at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in microscotomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to prescribed inhaled steroid regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child participant's movement during physiotherapy sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paediatric Quality of Life Inventory (PedsQL) results
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: System Usability Scale (SUS) results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in the area under the ROC curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Response rates to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in nociceptive brain response after duloxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neural network change (resting condition) induced by duloxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Early Detection of Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Steroid profile in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events (Grade 2 or Higher)
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose metabolism assessed by oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipolytic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of Panic Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of Physical Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Agoraphobic Cognitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Response at the Test of Cure Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity by ETDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥0.5 Log Reduction in the Number of EBV-infected B Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 2-fold or Greater Increase in NKG2D Expression in CD8 T+ Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Intima Media thickness of carotid arteries from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in high sensitive C- Reactive protein from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis Area and Severity index change (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of CD25 Pos/FoxP3 Positive Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of CD4 Pos/FOXP3 Positive Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-10 Staining Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of IL-10 Secreted by Adenoid Cells After PHA Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of TGF Secreted by Adenoid Cells After PHA Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes